Pipeline: Presbyopia, night vision disturbance up next for Vyluma


Presbyopia and night vision disturbance will follow myopia as a clinical focus for Vyluma. Navneet Puri, PhD, the company’s founder, chairman, and CEO, shares what is next.

Related Videos
Brianna Rhue, OD, FAAO, FSLS
Justin Kwan, OD, FAAO
Kevin Chan, OD, MS, FAAO, presents "Top 5 myopia management myths and how to overcome them" at AOA 2023 in Washington DC
© 2023 MJH Life Sciences

All rights reserved.